5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
October 2025 in “Cosmetics” Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
December 2025 in “PubMed” Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
2 citations
,
August 2023 in “Journal of the American Academy of Dermatology” New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.
August 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
1 citations
,
January 2021 PRP is effective for treating patchy alopecia areata.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
February 2026 in “International Journal of Dermatology” Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
15 citations
,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
New hair regrowth therapies show promise but need more research.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
June 2020 in “Journal of Investigative Dermatology” The symposium highlighted the importance of genetics in understanding and treating complex skin diseases.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.